Please assess the completion status of the following clinical trial:

Trial Title: Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Meet Rome III criteria for IBS and have no red flags.~* Must have had a colonoscopy within the previous 5 years to exclude inflammatory or other bowel disease~* Be fluent and literate in English~* Must either be of non-childbearing potential or agree to utilize approved birth control for the duration of the study~Exclusion Criteria:~* Diagnosis or treatment of any clinically symptomatic biochemical or structural abnormality of the GI tract within 6 months prior to screening, or active disease within 6 months prior to screening.~* Any other diagnosis to explain the abdominal pain,~* Clinical evidence of significant cardiovascular, respiratory, renal, hepatic, gastrointestinal, hematologic, neurologic, psychiatric or any disease that may interfere with the subject successfully completing the trial~* Hepatic dysfunction (ALT \[SGPT\] or AST \[SGOT\] \>3 times the upper limit of normal) or renal impairment (serum creatinine \> 2mg/dL)~* Has disease affecting electrolytes balance, such as SIADH with serum Sodium less than 130mmol/L~* Any evidence of or treatment of malignancy (other than localized basal cell, squamous cell skin cancer or cancer in situ that has been resected) within the previous year~* Any surgery on the stomach, small intestine or colon, excluding appendectomy~* A major psychiatric disorder (DSM-III-R or DSM-IV) including major depression or other psychoses that has required hospitalization in the last 1 year.~* History of attempted suicide or uncontrolled bipolar disorder.~* Currently using antidepressants for psychiatric conditions like major depression. Use of TCA or SSRI class antidepressant acceptable if being used specifically for treatment of bowel symptoms and patient is willing to taper off the medication~* Previous use of Milnacipran or other SNRI antidepressant (duloxetine, venlafaxine, desvenlafaxine)~* A diagnosis of seizure disorder~* A diagnosis of glaucoma~* Currently taking heparin or warfarin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Group A (50mg - 100mg) (Type: EXPERIMENTAL): Group A will begin treatment with Milnacipran 50mg BID (n=20) during Phase I and will be increased to 100mg BID during Phase II
- Group B (50mg x12) (Type: ACTIVE_COMPARATOR): Subjects in this arm will be maintained at Milnacipran 50mg BID for the entirety of the 12 weeks of the study.
- Group C (Placebo - 50mg) (Type: PLACEBO_COMPARATOR): Group C will begin treatment with Placebo BID (n=20) during Phase I and will be given 50mg BID during Phase II

Based on this trial design, predict the completion outcome and termination type (if applicable).